文献速递慢性肾脏病

蛋白尿与估算白蛋白尿对CKD风险预测的比较

Proteinuria, measured or estimated albuminuria for risk prediction in patients with chronic kidney disease?
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

该研究纳入2099例CKD 1-5级患者,比较实测白蛋白尿(mACR)、估算白蛋白尿(eACR)和蛋白尿(PCR)对5年肾脏替代治疗风险的预测性能。结果显示三者预测性能均优异,但eACR在低白蛋白尿患者中劣于mACR,且PCR在严重白蛋白尿和肾病范围蛋白尿中预测性能优于mACR。

要点

  • eACR在低白蛋白尿患者中显著低估mACR。
  • eACR在低白蛋白尿患者中预测性能劣于mACR。
  • PCR在严重白蛋白尿和肾病范围蛋白尿中预测性能优于mACR。

核心结论

  • mACR、eACR和PCR对CKD患者KFRT预测性能均优异,但低白蛋白尿患者中eACR劣于mACR,提示应实测而非估算白蛋白尿。

研究设计与样本

  • 来自韩国CKD患者结局队列研究,纳入2099例CKD 1-5级且无需肾脏替代治疗的患者,测量mACR和PCR并估算eACR,计算KFRE评分。

主要发现

  • eACR在低白蛋白尿患者中显著低估mACR。
  • 所有KFRE评分的时依ROC曲线显示预测性能优异。
  • 除病因未分类组外,所有CKD病因组中eACR的cNRI和IDI均劣于mACR。
  • 低白蛋白尿(<30 mg/g)患者中,eACR和PCR的cNRI和IDI均劣于mACR。
  • 严重白蛋白尿和肾病范围蛋白尿中,PCR的IDI和cNRI大于mACR。

关键数值与推荐

  • 低白蛋白尿定义为<30 mg/g;主要结局为5年KFRT风险。

临床怎么用

  • 低白蛋白尿患者优先实测白蛋白尿而非估算;严重白蛋白尿和肾病范围蛋白尿可考虑PCR预测。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although albuminuria is the gold standard for defining chronic kidney disease (CKD), total proteinuria has also been widely used in real-world clinical practice. Moreover, the superiority of the prognostic performance of albuminuria over proteinuria in patients with CKD remains inconclusive. Therefore, we aimed to compare the predictive performances of albuminuria and proteinuria in these patients. METHODS: From the Korean Cohort Study for Outcome in Patients with CKD we included 2099 patients diagnosed with CKD grades 1-5 who did not require kidney replacement therapy. We measured the spot urine albumin:creatinine ratio (mACR) and protein:creatinine ratio (PCR) and estimated the ACR (eACR) using the PCR. Kidney failure risk equation (KFRE) scores were calculated using the mACR, PCR and eACR. The primary outcome was the 5-year risk of kidney failure with replacement therapy (KFRT). RESULTS: The eACR significantly underestimated mACR in patients with low albuminuria levels. The time-dependent area under the receiver operating characteristics curve showed excellent predictive performance for all KFRE scores from the mACR, PCR and eACR. However, eACR was inferior to mACR based on the continuous net reclassification index (cNRI) and integrated discrimination improvement index (IDI) in all CKD cause groups, except for the group with an unclassified aetiology. Moreover, the cNRI and IDI statistics indicated that both eACR and PCR were inferior to mACR in patients with low albuminuria (<30 mg/g). Conversely, the predictive performance of PCR was superior in severe albuminuria and nephrotic-range proteinuria, in which the IDI and cNRI of the PCR were greater than those of the mACR. CONCLUSIONS: The mACR, eACR and PCR showed excellent performance in predicting KFRT in patients with CKD. However, eACR was inferior to mACR in patients with low albuminuria, indicating that measuring rather than estimating albuminuria is preferred for these patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kim H, Hyun YY, Joo YS, et al. Proteinuria, measured or estimated albuminuria for risk prediction in patients with chronic kidney disease? Nephrol Dial Transplant. 2024. PMID: 37723608. doi:10.1093/ndt/gfad195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。